Abstract:Several patients do not benefit from anti-cancer immunotherapies due to resistance for metabolic adaptation and fitness of tumor cells. Highly glycolytic tumor cells outcompete effector T cells for glucose in the tumor microenvironment (TME), impairing T cell function. High levels of lactate dehydrogenase (LDH) correlate with poor prognosis in cancer patients undergoing immunotherapies, inducing aberrant angiogenesis by activating HIF-1α and VEGF expression in endothelial cells (ECs), underscoring a biological interplay between tumor metabolism and neo-angiogenesis that can impact anti-tumor immunity. Main vasculature cells – ECs and pericytes (PCs) – may serve as antigen-presenting cells (APC), influencing T cell responses. While these findings point to a joint metabolic and immune regulation of the vasculature:T-cell crosstalk in the TME, we currently lack a precise understanding of the mechanisms linking tumor metabolism, aberrant angiogenesis, and anti-tumor T-cell responses, and how cell-based therapy may be influence by these factors. We have compared and contrasted vasculature and immune cells phenotypes by high-dimensional flow cytometry in established tumor models representing three major metabolic states by perturbing the two main cellular hubs for producing energy (aerobic glycolysis, by LDHA knock-down; oxidative phosphorylation, by depleting mitochondria as in Rho0 cells) compared to control tumors (NC). We functionally tested the impact of intratumor T cell recruitment according to these phenotypes, by adoptive cell transfer (ACT) therapy using T cells from donor mice immunized with matched-tumor injected i.v. in RAG2 KO mice bearing metabolically-defective tumor (KD or Rho0) and control tumor (NC) in contralateral mammary fat pad. We found that glycolysis-low tumors (LDH-A KD) show a better vasculature with reduced proportions of angiogenic activated PCs (cluster1: NG2+PDGFRbneg) and increased frequencies of "stabilizing" PCs (cluster 2: NG2negPDGFRb+, which counteract the formation of leaky vessels), compared to NC. However, KD tumors also display a reduction in MECA-79+ high endothelial venules. Moreover, LDHA-KD vs. NC tumors displayed ECs and cluster 2 PCs with greater expression of MHCI and decreased expression of FAS-L, and more EC expressing MHCII or PD-L1. In addition, the immune infiltrate of KD tumors is characterized by increased amounts of T effector cells and lower amounts of Gr1-low myeloid derived suppressor cells (MDSCs). The changes in vascularization phenotype have been confirmed in RAG2 KO mice bearing bilateral tumor variants model. ACT in these mice bearing bilateral 4T1-NC and -KD tumors resulted in greater biodistribution of T cells in the KD tumors, showing decreasing tumor growth. Vasculature features correspond to greater intratumor T-cell trafficking, indicating a mechanistic link between tumor glycolysis, aberrant angiogenesis, and T-cell exclusion. This would aim to elucidate the mechanisms through which these processes are connected for developing more efficacious T-cell-targeted therapies. Citation Format: Giorgia Colombo, Jee Hye Kang, Inna Serganova, Roberta Zappasodi. Interplay between tumor metabolism, vasculature, and T-cell infiltration in anti-tumor immunity [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy; 2024 Oct 18-21; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2024;12(10 Suppl) nr B049.

Aerobic glycolysis but not GLS1-dependent glutamine metabolism is critical for anti-tumor immunity and response to checkpoint inhibition

Restricting Glycolysis Preserves T Cell Effector Functions and Augments Checkpoint Therapy

Tumor glucose metabolism and the T cell glycocalyx: implication for T cell function

Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression

Targeted inhibition of tumor-specific glutaminase diminishes cell-autonomous tumorigenesis.

Tumor Aerobic Glycolysis Confers Immune Evasion Through Modulating Sensitivity to T Cell-Mediated Bystander Killing Via TNF-α.

Pharmacologic LDH inhibition redirects intratumoral glucose uptake and improves antitumor immunity in solid tumor models

The therapeutic implications of immunosuppressive tumor aerobic glycolysis

T cell metabolic fitness in antitumor immunity

Activation and antitumor immunity of CD8 + T cells are supported by the glucose transporter GLUT10 and disrupted by lactic acid

Targeting glycolysis for cancer therapy using drug delivery systems

Metabolic reprogramming of antitumor CD8+ T cells by modulation of GSH-Gpx4 axis

Targeting glutamine metabolism enhances tumor specific immunity by inhibiting the generation of MDSCs and reprogramming tumor associated macrophages

Targeting GLS1 to cancer therapy through glutamine metabolism

Abstract B049: Interplay between tumor metabolism, vasculature, and T-cell infiltration in anti-tumor immunity

Aerobic Glycolysis Controls Myeloid-Derived Suppressor Cells and Tumor Immunity Via a Specific CEBPB Isoform in Triple-Negative Breast Cancer.

Hurdle or Thruster: Glucose Metabolism of T Cells in Anti-Tumour Immunity

Aerobic Glycolysis Promotes Tumor Immune Evasion by Hexokinase2-Mediated Phosphorylation of IκBα.

PHGDH-mediated Endothelial Metabolism Drives Glioblastoma Resistance to Chimeric Antigen Receptor T Cell Immunotherapy.

Metabolic Plasiticy in Cancers—Distinct Role of Glycolytic Enzymes GPI, LDHs or Membrane Transporters MCTs

Glucose-dependent glycosphingolipid biosynthesis fuels CD8 T cell function and tumor control